All Articles

Sacituzumab govitecan-hziy has been granted full FDA approval for the treatment of metastatic triple-negative breast cancer. It has also been included in the NCCN Breast Cancer Guidelines based on convincing clinical evidence.

Sacituzumab govitecan-hziy, for the second-line treatment of patients with metastatic triple-negative breast cancer, is a cytotoxic drug that has specific storage, reconstitution, and administration instructions for adherence.

The optimal risk-to-benefit dosage of sacituzumab govitecan-hziy is 10 mg/kg, calculated from dose-escalation and dose-expansion studies.

Antibody–drug conjugates are at the leading edge of innovation and efficacy in breast cancer treatment. Research efforts continue in order to establish further novel targets and thus further advance patient outcomes.

A series of interviews was recently conducted with a panel of experts on prostate cancer imaging modalities that included Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, and Neal D. Shore, MD, FACS, CMO, Surgical Oncology/Urology Genesis Care, US; Director, CPI, Carolina Urologic Research Center, Myrtle Beach, SC.

Perioperative SOX treatment significantly improved 3-year disease-free survival in patients with locally advanced gastric cancer compared with adjuvant CapOx.

Results from a phase 2 clinical trial of the use of zanidatamab with standard first-line chemotherapy in patients with HER2-positive GEA show promising disease control rate and duration of response.

Results from a second-line trastuzumab deruxtecan phase 2 study in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer reveal promising response and safety.

Comprehensive analysis of immune checkpoints in gastric adenocarcinoma finds ICOSLG and CD70 may serve as prognostic biomarkers for gastric cancer.

Updated clinical data from the PANTHERA study shows promising efficacy for pembrolizumab triple therapy in HER2-positive advanced gastric and gastroesophageal junction (GEJ) cancer regardless of a patient’s PD-L1 status.